» Articles » PMID: 6143666

Propranolol Vs Metoprolol Vs Labetalol: a Comparative Study in Essential Hypertension

Overview
Specialty Pharmacology
Date 1984 Jan 1
PMID 6143666
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

In a double blind, within patient investigation of twenty-four patients (nineteen males and five females) with a mean age of 46.3 years (SD 10.9 years) with mild to moderate essential hypertension a comparison between equipotent beta-blocking doses of propranolol, metoprolol and labetalol was carried out. Blood pressure and pulse rate were measured in lying, sitting and standing positions and before, during and after isometric and dynamic exercise. Peak expiratory flow was recorded before and during dynamic exercise. All the active treatments were better than placebo in reducing blood pressure and heart rate. Comparing the effects of treatment, labetalol lowered sitting diastolic pressure significantly more than propranolol and standing diastolic pressure than both propranolol and metoprolol. Metoprolol and propranolol were more effective in reducing heart rate. Propranolol significantly reduced peak flow rate compared to labetalol. During the exercise, both isometric and dynamic, the heart rate and the blood pressure, both systolic and diastolic, of the treated patients were lower than those on placebo. There was little difference between the drugs in the influence on blood pressure, but metoprolol and propranolol were significantly more effective than labetalol in lowering the heart rate.

Citing Articles

Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.

Wong G, Laugerotte A, Wright J Cochrane Database Syst Rev. 2015; (8):CD007449.

PMID: 26306578 PMC: 6486308. DOI: 10.1002/14651858.CD007449.pub2.


Blood pressure lowering efficacy of nonselective beta-blockers for primary hypertension.

Wong G, Wright J Cochrane Database Syst Rev. 2014; (2):CD007452.

PMID: 24585007 PMC: 10603273. DOI: 10.1002/14651858.CD007452.pub2.


New drugs for the treatment of hypertension: where do they fit?.

Wilson T, Dubois M Can Fam Physician. 2011; 33:2583-9.

PMID: 21264001 PMC: 2218698.


Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Peters D, Benfield P Pharmacoeconomics. 1994; 6(4):370-400.

PMID: 10147474 DOI: 10.2165/00019053-199406040-00004.


Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Benfield P, Clissold S, Brogden R Drugs. 1986; 31(5):376-429.

PMID: 2940080 DOI: 10.2165/00003495-198631050-00002.


References
1.
Ablad B, LJUNG B, SANNERSTEDT R . Haemodynamic effects of beta-adrenorecptor blockers in hypertension. Drugs. 1976; 11 SUPPL 1:127-34. DOI: 10.2165/00003495-197600111-00028. View

2.
HOOBLER S, Oesterle B, Early H . Evaluation of a new automatic device for taking and recording blood pressures. J Lab Clin Med. 1976; 88(5):826-33. View

3.
van Herwaarden C, Binkhorst R, Fennis J, vant Laar A . Effects of propranolol and metoprolol on haemodynamic and respiratory indices and on perceived exertion during exercise in hypertensive patients. Br Heart J. 1979; 41(1):99-105. PMC: 482016. DOI: 10.1136/hrt.41.1.99. View

4.
KUBIK M, Coote J . Comparison of the antihypertensive effects of indapamide and metoprolol. Postgrad Med J. 1981; 57 Suppl 2:44-50. View

5.
Mitchell J, Wildenthal K . Static (isometric) exercise and the heart: physiological and clinical considerations. Annu Rev Med. 1974; 25:369-81. DOI: 10.1146/annurev.me.25.020174.002101. View